RxDoctor Payments Data
★ My doctorsLook up a doctor →

Aditya Bardia, MD

Hematology & Oncology · Santa Monica, CANPI 1639210107

Payments from drug & device makers

What this record shows

This record is dominated by consulting fees: $484,824 of the $593,426 with a category attached, or 81.7%. It is spread thinly across 29 manufacturers, the largest accounting for just 21.0%. Reporting peaked in 2023 at $124,756 and has fallen 69.1% since, to $38,522 in 2025. Among hematology & oncology clinicians in CA with any reported payments, this total sits in the top 5% — high for the specialty, which is a reason to read the composition above rather than the number alone.

$593,426in general payments, 2019–2025

Across 372 payments — averaging $1595.23 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • Gilead$125K
  • Astrazeneca UK Limited$72K
  • Novartis$64K
  • Sanofi-aventis U.S. LLC$45K
  • Merck$32K
  • AstraZeneca$30K
  • plus $226K from 23 others
$21,599,183in research payments, 2019–2025

Across 754 payments — averaging $28,646 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.

  • Novartis$10.9M
  • Pfizer$3M
  • Genentech, Inc.$2M
  • AstraZeneca$1.6M
  • Gilead$991K
  • Sanofi US Services Inc.$886K
  • plus $2.2M from 13 others

What the payments were for

  • Consulting fees$484,82482%
  • Speaking & faculty fees$40,8577%
  • Travel & lodging$60,77110%
  • Food & beverage$6,9621%
  • Education$120%

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

CompanyPaymentsTotal
Gilead57$124,859
Astrazeneca UK Limited47$71,719
Novartis30$64,235
Sanofi-aventis U.S. LLC13$44,934
Merck24$32,371
AstraZeneca26$29,678
Eli Lilly32$26,282
Radius Health, Inc.13$21,352
Stemline Therapeutics Inc.9$20,928
F. Hoffmann-la Roche AG22$20,792
E.r. Squibb & Sons, L.L.C.10$17,726
Lilly USA, LLC2$15,300
Sanofi9$14,316
Roche Products Limited14$14,077
Philips North America LLC8$13,346
Daiichi Sankyo Inc.8$11,528
Genentech USA, Inc.6$9,667
Puma Biotechnology, Inc.13$9,421
Foundation Medicine, Inc.6$6,637
Pfizer8$6,615
Seagen Inc.2$3,648
Immunomedics, Inc.2$2,750
Daiichi Sankyo Europe GmbH1$2,500
Daiichi Sankyo Company LTD1$2,363
Eisai Inc.1$2,040
Sanofi US Services Inc.2$1,500
Delcath Systems1$1,200
Genentech, Inc.4$840
Aadi Bioscience, Inc.1$800

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$593,426 in reported general payments places this provider in the 95th percentile of 1,363 hematology & oncology providers in California.

See all hematology & oncology providers in California →

Medicare billing

Part B allowed, 2024
$43,710
Medicare patients
55
Services billed
1,649

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Other hematology & oncology in Santa Monica

See the full list for California →

Where these figures come from

Is this you, or does something look wrong? →